Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum.
about
Modulation of the lung inflammatory response to serotype 8 pneumococcal infection by a human immunoglobulin m monoclonal antibody to serotype 8 capsular polysaccharide.Use of licensed vaccines for active immunization of the immunocompromised hostProphylactic human papillomavirus vaccinesA human monoclonal immunoglobulin M reduces bacteremia and inflammation in a mouse model of systemic pneumococcal infectionNeutralizing antibodies protect against lethal flavivirus challenge but allow for the development of active humoral immunity to a nonstructural virus proteinProtein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1Computational prediction of broadly neutralizing HIV-1 antibody epitopes from neutralization activity dataPreparation, immunogenicity, and protective efficacy, in a murine model, of a conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of Vibrio cholerae O139 bound to tetanus toxoidPreparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virusNeutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140Topical vaccination: the skin as a unique portal to adaptive immune responses.Immunogenomics and systems biology of vaccines.International network for comparison of HIV neutralization assays: the NeutNet report.Vibrio cholerae O139 conjugate vaccines: synthesis and immunogenicity of V. cholerae O139 capsular polysaccharide conjugates with recombinant diphtheria toxin mutant in mice.A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolatesProtection against nontypeable Haemophilus influenzae challenges by mucosal vaccination with a detoxified lipooligosaccharide conjugate in two chinchilla modelsProtection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.HIV neutralizing antibodies: clinical correlates and implications for vaccines.Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis.Phase 1 evaluation of Vibrio cholerae O1, serotype Inaba, polysaccharide-cholera toxin conjugates in adult volunteers.Immunization against natural Helicobacter pylori infection in nonhuman primates.Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis.Serum IgG mediates mucosal immunity against rotavirus infectionAggregation of Streptococcus pneumoniae by a pneumococcal capsular polysaccharide-specific human monoclonal IgM correlates with antibody efficacy in vivoEpidermal powder immunization induces both cytotoxic T-lymphocyte and antibody responses to protein antigens of influenza and hepatitis B viruses.Measurement of neutralizing serum antibodies of patients vaccinated with human papillomavirus L1 or L2-based immunogens using furin-cleaved HPV Pseudovirions.Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?Immunoglobulin G subclass profile of antimeasles response in vaccinated children and in adults with measles history.Specific antibody levels at the cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 virus-like particles.Vaccination strategies for mucosal immune responsesOutcomes of Bordetella infections in vaccinated children: effects of bacterial number in the nasopharynx and patient ageSerum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters.Intranasal immunization with pneumococcal polysaccharide conjugate vaccines protects mice against invasive pneumococcal infections.Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in miceSafety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.Intranasal immunization with pneumococcal polysaccharide conjugate vaccines with nontoxic mutants of Escherichia coli heat-labile enterotoxins as adjuvants protects mice against invasive pneumococcal infections.Syntheses and immunologic properties of Escherichia coli O157 O-specific polysaccharide and Shiga toxin 1 B subunit conjugates in mice.Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam.Clostridium difficile recombinant toxin A repeating units as a carrier protein for conjugate vaccines: studies of pneumococcal type 14, Escherichia coli K1, and Shigella flexneri type 2a polysaccharides in mice.Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.
P2860
Q24532019-AB943DD7-D9E6-4502-942E-63AC882A0AC9Q24533456-220D6C4E-4448-4BC8-AE2D-2A37CE3F3EA3Q24545449-B4C809E2-E429-4C44-8756-D90F47512677Q24672825-53543F2B-B55A-4AD1-8EFC-0D28CC776409Q27469558-B67337B1-C228-458B-A37D-E9B34BD2A765Q28343287-D1E687AC-9957-4118-83E9-DB063F0A8780Q28535583-D0B460C6-F044-42E3-8281-D09273356E82Q30328099-C45F2849-AF50-46C2-920D-9A4FFD0A5FDDQ30379914-2A3FC9ED-B1BE-4319-9B55-74F4675F023BQ30431941-2872F55D-972C-4983-9B63-F23C2FE901B3Q33290410-0507C94E-0A1C-4793-96CA-899621699C6FQ33350387-4B820E4B-D2D8-401C-93BD-D928DEF40438Q33410826-3827CCCB-B18F-457B-A972-11C381E21829Q33598485-DDD44D33-9EAC-409D-8577-CC9AF65EDA57Q33603494-A959D6B9-CCE0-4239-B51D-FF18595EDED3Q33636649-D9F712EA-7AD3-4E48-A43F-540BC715A94FQ33647300-748823B2-3DB7-4442-9199-126E0286249FQ33703451-A4A2F1BE-38F9-4221-88C0-EF5ECECA33B5Q33753424-6E4972A8-D4BA-4418-BAC2-24F45F14473CQ33756057-F7370559-9630-404C-8016-7D24961ADBCBQ33762386-261CBA42-C87A-4571-ACCD-337313335B91Q33768943-BCCD1033-B8CF-4EB0-A195-48517A3748B6Q33821665-B326506A-4845-4966-AD75-C966BCC0702AQ33825652-900BF359-DDA1-421D-A77B-808AFEFE2542Q33849973-9A2EE53F-3270-410C-8AC9-773FC599D107Q33856453-42C2C026-46CD-4FB5-96DA-8ABBC2E26AFBQ33887693-36BADEE0-E306-4E3A-9525-B3FA2429E6ACQ33910783-288CAD4B-51AF-4888-A467-79C1DD9C2C77Q33967624-DF1EB50D-1F9B-405B-B469-8FC7BD5110F1Q33975703-DB413EEA-4C2D-4D99-9279-CE5623037EC4Q33997750-A571814A-F8CE-43D1-83F0-7765AA1A64D5Q34000146-85C4D2B6-8954-44E6-ACBA-6957D5AA632BQ34001509-B37E80C2-9A4A-4ACA-8F6C-973FEDB6CDB7Q34002272-C40579AA-7F8C-40E0-8462-8648A35D4110Q34002415-F0BE27FE-E43B-441E-AEC8-95EA15D70CB9Q34002470-612F0F99-0180-420E-AC06-4A1EC1784621Q34002606-B78DE1DA-3BDA-495E-BAEE-AA20EFC647EFQ34003647-2BC07911-9834-4298-8DF9-DB613B7F7FF0Q34003957-A87520EE-051D-4CE4-A580-D8BB1C43A800Q34006223-19E1E1AC-03FE-47DA-B3E2-56320FBF45AD
P2860
Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Perspective: hypothesis: serum ...... by inactivating the inoculum.
@en
type
label
Perspective: hypothesis: serum ...... by inactivating the inoculum.
@en
prefLabel
Perspective: hypothesis: serum ...... by inactivating the inoculum.
@en
P2093
P356
P1476
Perspective: hypothesis: serum ...... by inactivating the inoculum.
@en
P2093
P304
P356
10.1093/INFDIS/171.6.1387
P407
P577
1995-06-01T00:00:00Z